Board of directors (12)
Directors with a Section 16 filing in the last 13 months. “Since” is the first filing as a director; SEC data sets start in 2016.
Executive officers (9)
Company facts
- Chair
- Eric Mark Green
- In S&P 500 since
- May 2020
- Incorporated in
- PA
- Fiscal year ends
- December
- SEC industry
- Surgical & Medical Instruments & Apparatus
- SEC filings
- EDGAR
Connections to other S&P 500 companies
Current directors and officers who also hold a role at another S&P 500 company.
Major holders (5% or more)
Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.
No 5% holder filings parsed yet for this company.
Insider trades
Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | Annette F. Favorite Sr. VP & Chief HR Officer | Sale | 2,524 | $365.00 | $921K |
| Sep 14, 2026 | Annette F. Favorite Sr. VP & Chief HR Officer | Sale | 2,500 | $355.00 | $888K |
| Sep 11, 2026 | Annette F. Favorite Sr. VP & Chief HR Officer | Sale | 2,500 | $345.00 | $863K |
| Sep 8, 2026 | Annette F. Favorite Sr. VP & Chief HR Officer | Sale | 2,818 | $340.81 | $960K |
| Sep 8, 2026 | Annette F. Favorite Sr. VP & Chief HR Officer | Sale | 2,500 | $340.81 | $852K |
| Sep 8, 2026 | Annette F. Favorite Sr. VP & Chief HR Officer | Sale | 2,817 | $340.81 | $960K |
| Apr 27, 2026 | Annette F. Favorite Sr. VP & Chief HR Officer | Sale | 2,817 | $305.20 | $860K |
| Apr 27, 2026 | Chad Winters VP, Chief Accounting Officer | Sale | 896 | $300.67 | $269K |
| Oct 29, 2024 | Charles Witherspoon VP & Treasurer | Sale | 225 | $310.40 | $70K |
| Oct 29, 2024 | Charles Witherspoon VP & Treasurer | Sale | 478 | $310.40 | $148K |
| Aug 19, 2024 | Charles Witherspoon VP & Treasurer | Sale | 500 | $300.00 | $150K |
| Aug 19, 2024 | Charles Witherspoon VP & Treasurer | Sale | 529 | $300.00 | $159K |
| Aug 6, 2024 | Eric Mark Green President, CEO and Board Chair | Sale | 30,732 | $304.71 | $9.4M |
| Jun 12, 2024 | Silji Abraham SVP, Chief Technology Officer | Sale | 1,800 | $330.78 | $595K |
| May 10, 2024 | Thomas W. Hofmann Director | Sale | 617 | $365.92 | $226K |
| May 7, 2024 | Eric Mark Green President, CEO and Board Chair | Sale | 41,000 | $366.65 | $15.0M |
| May 7, 2024 | Eric Mark Green President, CEO and Board Chair | Sale | 15,684 | $366.66 | $5.8M |
| May 7, 2024 | Eric Mark Green President, CEO and Board Chair | Sale | 9,316 | $366.64 | $3.4M |
| Mar 11, 2024 | Chad Winters VP, Chief Accounting Officer | Sale | 815 | $358.82 | $292K |
| Feb 28, 2024 | Charles Witherspoon VP & Treasurer | Sale | 2,019 | $358.62 | $724K |
| Feb 27, 2024 | Eric Mark Green President, CEO and Board Chair | Sale | 64,132 | $359.85 | $23.1M |
| Feb 23, 2024 | Silji Abraham SVP, Chief Technology Officer | Sale | 7,012 | $365.00 | $2.6M |
| Dec 1, 2023 | Chad Winters VP, Chief Accounting Officer | Sale | 1,013 | $349.00 | $354K |
| Oct 31, 2023 | Charles Witherspoon VP & Treasurer | Sale | 594 | $322.48 | $192K |
| Oct 31, 2023 | Charles Witherspoon VP & Treasurer | Sale | 596 | $322.27 | $192K |
Board and executive changes
Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.
- Jun 1, 2026
On March 9, 2026, West Pharmaceutical Services, Inc. (the “Company”) filed a Current Report on Form 8-K announcing that Mr. Eric M. Green, President, Chief Executive Officer and Chair of the Board of Directors (the “Board”) of the Company, informed the Board on March 6, 2026 of his intent to retire from those positions once his successor has been hired in order to ensure a smooth transition. On June 1, 2026, the Company announced the appointment of Michel Lagarde as President and Chief Executive Officer of the Company, effective August 31, 2026 (the “Start Date”), to replace Mr. Green in those roles. As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy. As of the Start Date, Lead Independent Director Robert F. Friel will become Chair of the Board. Mr.
Read the 8-K filing - Mar 9, 2026
Today, March 9, 2026 , West Pharmaceutical Services, Inc. (the “Company”) announced that Mr. Eric M. Green, President, Chief Executive Officer and Chair of the Board of Directors (the “Board) of the Company, informed the Board on March 6, 2026 of his intent to retire from those positions once his successor has been hired in order to ensure a smooth transition. The Board is engaging a leading executive recruiting firm to assist with the search for a successor and expects this transition to occur in the second half of 2026.
Read the 8-K filing - Sep 11, 2025
Today, September 11, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the Company. The Company and Ms. MacKay have agreed to discuss an appropriate transition period which will end no later than December 31, 2025, to ensure continuity and a smooth and orderly transition of responsibilities. Ms. MacKay will continue her current duties until she leaves the Company. The Company extends its gratitude to Ms. MacKay for her exemplary service and contributions during her tenure and wishes her success in her future endeavors.
Read the 8-K filing - Jul 21, 2025
Appointment of New Senior Vice President & Chief Financial Officer On July 21, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced the appointment of Robert McMahon as Senior Vice President & Chief Financial Officer, effective as of August 4, 2025 (the “Commencement Date”). Mr. McMahon will serve on the Company's senior leadership team and will oversee finance, audit, treasury, tax, investor relations and procurement. Prior to joining West, Mr. McMahon, age 56, served as the Chief Financial Officer of Agilent Technologies Inc., a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. At Agilent, he was responsible for finance, audit, treasury, tax, investor relations, IT and procurement. From 2014 to 2018, Mr.
Read the 8-K filing - May 12, 2025
As noted on the original Form 8-K filed on May 8, 2025, the shareholders of the Company approved an amendment and restatement of the 2016 Omnibus Incentive Compensation Plan (the “Plan”). The material provisions of the amendment and restatement of the Plan are described extensively in our definitive proxy statement filed on March 21, 2025 and are qualified in their entirety by the amended and restated Plan attached as an exhibit 10.15 to this Form 8-K/A.
Read the 8-K filing - Apr 24, 2025
Retirement of Senior Vice President, Chief Financial Officer On April 22, 2025, Mr. Bernard Birkett notified West Pharmaceutical Services, Inc. (the “Company”) of his intention to retire as Senior Vice President & Chief Financial Officer later this year. The Company has initiated a search for Mr. Birkett’s successor and is implementing a comprehensive transition plan. Mr. Birkett will continue in his current role, remaining with the Company until a successor is found to ensure an effective transition. Then he will assume an advisory role until December 31, 2025. Appointment of New Senior Vice President, Chief Proprietary Segment Officer On April 24, 2025, the Company announced that it had appointed Shane Campbell to serve as Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025 (the "Commencement Date"). Mr.
Read the 8-K filing - Apr 14, 2025
On March 7, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Cindy Reiss-Clark, former Senior Vice President and Chief Commercial Officer, departed from the Company effective that same date. At the time of her departure, Ms. Reiss-Clark was a named executive officer of the Company. In accordance with the Company's standard severance policy, Ms. Reiss-Clark is entitled to severance benefits contingent upon her execution of a release in favor of the Company and its affiliates along with compliance with certain other covenants. Ms. Reiss-Clark and the Company have reached an agreement on the terms of a Separation Agreement and Release (the “Agreement”). The Agreement provides Ms.
Read the 8-K filing - Mar 11, 2025
On March 7, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Cindy Reiss-Clark, Senior Vice President and Chief Commercial Officer, has departed the Company, effective the same day. As part of this transition, her leadership responsibilities will be managed on an interim basis by Aileen Kinsella, the Company's Head of Proprietary Product Sales. The Company thanks Ms. Reiss-Clark for her contributions and service and wishes her the best in her future endeavors.
Read the 8-K filing - Dec 11, 2024
On December 9, 2024, West Pharmaceutical Services, Inc. (the "Company") elected Janet Haugen, to its Board of Directors (the "Board") as its newest member. With the addition of Ms. Haugen, the Board increased in size to 12 directors. Ms. Haugen is expected to participate on the Audit Committee of the Board as of the date of her appointment. Ms. Haugen, 66, is the former Chief Financial Officer of Unisys Corporation, a role she served in for more than 16 years. During her 20-year tenure at Unisys, Ms. Haugen oversaw the company’s business transformation from a mainframe hardware, software and maintenance company to an IT services and software provider. In addition to her core finance responsibilities at the company, she had oversight of Unisys’ corporate development, IT, procurement, facilities and legal functions. Prior to joining Unisys, Ms.
Read the 8-K filing - Oct 7, 2024
On October 1, 2024, Silji Abraham, Senior Vice President & Chief Technology Officer of West Pharmaceutical Services, Inc. (the “Company”), notified the Company that he intends to resign, effective December 31, 2024, to pursue other interests. The Company will work with Mr. Abraham and his leadership team to ensure a smooth transition of his duties prior to his departure. Mr. Abraham’s departure is not the result of any disagreement with the Company on matters related to operations, policies or practices, and he will receive no additional compensation as a result of his departure.
Read the 8-K filing - Apr 26, 2024
On April 26, 2024, West Pharmaceutical Services, Inc. (“West”) announced an update to the role of Bernard Birkett, Chief Financial and Operations Officer. Since May 2022, Mr. Birkett served as both our Principal Financial and Principal Operating Officer. Mr. Birkett‘s leadership while in this combined role has greatly enhanced the operations capabilities of both our Proprietary Products and Contract Manufacturing Business Segments. This now allows us to transfer much of our operational leadership and decision-making to each of our Business Segments to further improve our efficiency. Effective May 1, 2024, Mr. Birkett’s title will be solely Chief Financial Officer (“CFO”), where he will retain financial oversight for both Business Segments, operational oversight of our strategic sourcing function and be involved in key operational issues together with other members of our executive team.
Read the 8-K filing - Jul 27, 2022
On July 26, 2022, West Pharmaceutical Services, Inc. (the "Company") elected Stephen Lockhart, M.D., Ph.D., to its Board of Directors (the "Board") as its newest member. With the addition of Dr. Lockhart, the Board now has 11 directors. Dr. Lockhart, 64, a board-certified anesthesiologist, is the former Chief Medical Officer ("CMO") of Sutter Health, a not-for-profit system of hospitals, physician organizations and research institutions in Northern California. Serving in this role for over seven years, he was responsible for quality, patient safety, research and education. In addition, Dr. Lockhart is the founder and executive sponsor of the Sutter Health Institute for Advancing Health Equity. He was previously the regional CMO for Sutter Health East Bay. Prior to that, Dr. Lockhart was the chief administrative officer at St. Luke’s campus of California Pacific Medical Center ("CMPC").
Read the 8-K filing - May 12, 2022
On May 12, 2022, West Pharmaceutical Services, Inc. (the “Company” or "West") announced the appointment of Bernard J. Birkett, Chief Financial Officer, to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead the Company's Global Operations and Global Supply Chain. After six years of dedicated service, the Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo, has announced his resignation to pursue other interests, with a departure date of July 2022. The Company has also announced other leadership changes and additions, including the appointment of Cindy Reiss-Clark as the Chief Commercial Officer, which are described in further detail in the Company's press release.
Read the 8-K filing - Feb 28, 2022
After 20 years of dedicated service, Patrick Zenner informed West Pharmaceutical Services, Inc. (the “Company”) on February 22, 2022, of his intention to retire and not to stand for re-election as Chairman to the Company’s Board of Directors ("Board") at the next Annual Meeting of Shareholders, scheduled to be held on May 24, 2022 (the “Annual Meeting”). Mr. Zenner will continue to actively serve on the Company’s Board until the Annual Meeting. Mr. Zenner has informed the Company that there is no disagreement between him and the Company on any matter relating to its operations, polices or practices. Eric M. Green, President and Chief Executive Officer ("CEO"), will assume the additional responsibility of Chair of the Company's Board upon Mr. Zenner's retirement.
Read the 8-K filing - Aug 24, 2021
and its accompanying press release incorrectly indicated that Ms. Joseph was the Chief Executive Officer (“CEO”) of UnitedHealthcare Group. Ms. Joseph was the CEO of UnitedHealthcare Global and Executive Vice President of UnitedHealth Group. Other than as required to correct the error described above, as reflected in the below restated
Read the 8-K filing
Show 16 older changes
- Aug 23, 2021
On August 19, 2021, West Pharmaceutical Services, Inc. (the "Company") elected Molly Joseph to its Board of Directors (the "Board") as its newest member. With the addition of Ms. Joseph, the Board increased in size to 11 directors. Ms. Joseph is expected to participate on the Finance Committee and Innovation and Technology Committee of the Board. Ms. Joseph, 47, is the former Chief Executive Officer ("CEO") of UnitedHealthcare Group, a role she served in for more than a decade. During her 16-year tenure, she pioneered the establishment of UnitedHealth Group’s global health business into one of the largest health benefits and medical delivery businesses outside of the United States. As CEO of UnitedHealthcare Global, she ha d oversight of more than 50 hospitals and several hundred ambulatory centers which served over 9 million patients and 7 million insurance members. Ms.
Read the 8-K filing - May 6, 2021
On May 4, 2021, the Board of Directors (the "Board") approved a material amendment to the 2016 Omnibus Incentive Compensation Plan (the “Plan”) to reduce the number of equity awards that may be issued under the Plan without regard to any service vesting requirements. The amendment is attached to this filing as Exhibit 10.36. Prior to the amendment, the Plan permitted up to 10% of the 5,500,000 shares of common stock reserved for issuance to be issued without regard to any service vesting requirements. Effective May 4, 2021, this limitation has been reduced from 10% to 5% of the shares of common stock reserved for issuance. Therefore, now only up to 275,000 shares may be issued without regard to vesting requirements. Equity awards issued under the Plan without regard to vesting requirements before the date of the amendment count against the revised limit.
Read the 8-K filing - Mar 1, 2021
After 17 years of dedicated service, Paula A. Johnson informed West Pharmaceutical Services, Inc. (the “Company”) on February 23, 2021, of her intention not to stand for re-election to the Company’s Board of Directors ("Board") at the next Annual Meeting of Shareholders, scheduled to be held on May 4, 2021 (the “Annual Meeting”), in order to pursue other interests. Dr. Johnson will continue to actively serve on the Company’s Board until the scheduled May 4, 2021 Annual Meeting. Dr. Johnson has informed the Company that there is no disagreement between her and the Company on any matter relating to its operations, polices or practices.
Read the 8-K filing - Nov 9, 2020
On November 4, 2020, George L. Miller informed the Company that he intends to retire effective at the end of February 2021. He will step down in his role as Senior Vice President, General Counsel and Corporate Secretary effective December 8, 2020 after which he will become a Special Advisor to our President and Chief Executive Officer, Eric M. Green where, among other things, he will assist with transition of his duties. His departure is not based on any disagreement with the Company relating to its operations, policies or practices. In connection with his retirement, no additional compensation was agreed. Kimberly Banks MacKay, 55, has agreed to join the Company as its new Senior Vice President, General Counsel and Corporate Secretary. She will join the Company on December 2, 2020 and will report directly to Mr. Green.
Read the 8-K filing - May 7, 2020
Appointment of New Principal Accounting Officer On May 5, 2020, West Pharmaceutical Services, Inc. (the “Company” and “our”) promoted Chad R. Winters to serve as Vice President, Chief Accounting Officer and Corporate Controller, effective immediately, and appointed him our new Principal Accounting Officer. Mr. Winters is assuming the role of Principal Accounting Officer from Bernard J. Birkett, who continues his role as Senior Vice President and Chief Financial Officer. Mr. Winters’ promotion reflects our normal talent management planning for this role. Mr. Birkett stepping down as Principal Accounting Officer is not the result of any dispute, and he will continue to serve as our Chief Financial Officer. Mr. Winters, 42, was appointed our Vice President and Corporate Controller in October 2019, with responsibility for the accounting, U.S.
Read the 8-K filing - Feb 18, 2020
On February 17, 2020, West Pharmaceutical Services, Inc. (the “Company”) announced that its Board of Directors (the “Board”) had elected Robert Friel as its newest member. With the addition of Mr. Friel, the Board increased in size to 11 directors. Mr. Friel, age 64, recently retired as Chairman and Chief Executive Officer of PerkinElmer, Inc., a role he served in for more than 10 years. During his 20-year career at PerkinElmer, a global business dedicated to serving the diagnostics, life sciences, food and applied markets, Mr. Friel held roles of increasing responsibility that included Chief Operating Officer, President of the Life and Analytical Sciences Division and Chief Financial Officer. Prior to joining PerkinElmer, Mr. Friel served in several finance-focused senior management positions with AlliedSignal, Inc., now Honeywell International. Mr.
Read the 8-K filing - Nov 21, 2019
On November 19, 2019, Ms. Karen Flynn, Senior Vice President and Chief Commercial Officer, informed Mr. Eric Green, President and Chief Executive Officer of West Pharmaceutical Services, Inc. (the “Company”), of her intention to step down from her role and retire as of December 31, 2019. In connection with Ms. Flynn’s retirement, Ms. Cindy Reiss-Clark has been promoted to Senior Vice President of Global Market Units and Commercial Solutions from her previous role of Vice President and General Manager of the Company’s Biologics Market Unit, and Mr. Christopher Ryan has been promoted to Senior Vice President of Commercial Products and Emerging Markets from his previous role of Vice President and General Manager of the Company’s Generics Market Unit. Ms.
Read the 8-K filing - Oct 2, 2019
On September 27, 2019, West Pharmaceutical Services (the “Company”) appointed Senior Vice President, Chief Financial Officer and Treasurer, Bernard J. Birkett, to the role of Principal Accounting Officer, effective as of October 7, 2019, following the decision of Daniel Malone, Vice President and Corporate Controller, to retire on December 31, 2019. Mr. Birkett’s appointment will be in addition to his current duties. Mr. Malone’s departure is not related to any disagreement with the Company’s accounting, operating policies or practices. No new compensatory arrangements will be entered into with Mr. Birkett in connection with his appointment as the Company’s Principal Accounting Officer. Mr. Birkett was not appointed as the Company’s Principal Accounting Officer pursuant to any arrangement or understanding with any other person. Mr.
Read the 8-K filing - Feb 27, 2019
After 12 years of dedicated service, John H. Weiland informed West Pharmaceutical Services, Inc. (the “Company”) on February 19, 2019, of his intention not to stand for re-election to the Company’s Board of Directors at the next Annual Meeting of Shareholders, scheduled to be held on May 7, 2019 (the “Annual Meeting”), in order to pursue other interests. Mr. Weiland will continue to actively serve on the Company’s Board of Directors until the Annual Meeting. Mr. Weiland has informed the Company that there is no disagreement between himself and the Company on any matter relating to its operations, polices or practices. 2
Read the 8-K filing - Jun 21, 2018
Appointment of New Senior Vice President, Chief Financial Officer and Treasurer On June 21, 2018, West Pharmaceutical Services, Inc. (the “Company”) announced that it had appointed Bernard J. Birkett to serve as Senior Vice President, Chief Financial Officer and Treasurer, effective June 21, 2018 (the “Commencement Date”). Mr. Birkett will serve on the Company’s senior leadership team and will oversee the Company’s entire Finance function. Mr. Birkett, 49, joins the Company from Merit Medical Systems, Inc., a leading manufacturer of disposable medical devices, where he most recently served as Chief Financial Officer and Treasurer. Over a 20-year career at Merit, Mr. Birkett served in a number of senior global leadership roles, including Controller for Europe, Middle East and Africa (EMEA) and Vice President of International Finance. Mr.
Read the 8-K filing - Mar 2, 2018
On March 2, 2018, William J. Federici, Senior Vice President, Chief Financial Officer & Treasurer, announced his intention to retire later this year.
Read the 8-K filing - Jul 20, 2017
On June 1, 2017, West Pharmaceutical Services, Inc. (the “Company”) announced that its Board of Directors (the “Board”) had elected Deborah Keller as its newest member. With the addition of Ms. Keller, the Board increased in size to 11 directors. On July 18, 2017, Ms. Keller was appointed to the Innovation and Technology Committee.
Read the 8-K filing - Jun 1, 2017
On June 1, 2017, West Pharmaceutical Services, Inc. (the “Company”) announced that its Board of Directors (the “Board”) had elected Deborah Keller as its newest member. With the addition of Ms. Keller, the Board increased in size to 11 directors. Ms. Keller, 54, has served as a Principal at Black Frame Advisors, LLC, an advisory and consulting firm, since her retirement as Chief Executive Officer (“CEO”) of Covance Drug Development, a business segment of Laboratory Corporation of America ® Holdings, in October 2016. Prior to her appointment as CEO in July 2015, Ms. Keller spent more than 28 years at Covance in a number of leadership roles, including Corporate Executive Vice President and Group President of Research and Development Laboratories, Corporate Senior Vice President and President of Discovery and Translational Services, and Vice President of Analytical Services in Europe.
Read the 8-K filing - Sep 26, 2016
Appointment of New Senior Vice President, Global Operations and Supply Chain On September 26, 2016, West Pharmaceutical Services, Inc. (the "Company") announced that it had appointed David A. Montecalvo to serve as Senior Vice President, Global Operations and Supply Chain, effective September 26, 2016 (the "Commencement Date"). Mr. Montecalvo will serve on the Company's senior leadership team and will oversee the Company’s Global Operations function. Mr. Montecalvo, 51, joins the Company from Medtronic plc, where he served in a number of senior leadership roles, including Vice President, Contract Manufacturing Operations, for the company’s Restorative Therapies Group, a $7 billion group of businesses; and Vice President, Business Operations Integration, where he was responsible for directing and leading the global operations integration of Covidien plc into Medtronic.
Read the 8-K filing - Sep 12, 2016
On September 12, 2016, West Pharmaceutical Services, Inc. (the "Company") announced that its Board of Directors (the "Board") had elected Paolo Pucci to fill the vacancy following the retirement of Anthony Welters. Mr. Pucci, 55, is Chief Executive Officer of ArQule, Inc., a biopharmaceutical company engaged in the research and development of targeted therapeutics. Prior to his joining ArQule in 2008, Mr. Pucci worked at Bayer A.G., where he served in a number of leadership capacities including Senior Vice President of the Global Specialty Medicine Business Unit and was a member of the Bayer Pharmaceuticals Global Management Committee. Mr. Pucci will be entitled to the customary compensation arrangements for the Company’s non-employee directors, which consists of an $80,000 annual retainer and a restricted stock unit grant of $160,000, both prorated based on Mr.
Read the 8-K filing - Feb 29, 2016
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing
Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021
Share price
Annual financials
From the company's 10-K XBRL data (SEC companyfacts).
| Fiscal year | Revenue | Net income | Margin | Diluted EPS | Total assets |
|---|---|---|---|---|---|
| FY2025 | $3.1B | $493.7M | 16.1% | $6.79 | $4.3B |
| FY2024 | $2.9B | $492.7M | 17.0% | $6.69 | $3.6B |
| FY2023 | $2.9B | $593.4M | 20.1% | $7.88 | $3.8B |
| FY2022 | $2.9B | $585.9M | 20.3% | $7.73 | $3.6B |
| FY2021 | $2.8B | $661.8M | 23.4% | $8.67 | $3.3B |
| FY2020 | $2.1B | $346.2M | 16.1% | $4.57 | $2.8B |
| FY2019 | $1.8B | $241.7M | 13.1% | $3.21 | $2.3B |
| FY2018 | $1.7B | $206.9M | 12.0% | $2.74 | $2.0B |
Former directors and officers (20)
People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.